Extremely significant negative changes in Haemonetics Corp (NYSE: HAE) investment behavior have recently occurred: the stock’s recent price decline challenged its longer term uptrend, the stock fell on very heavy volume, and negative upside/downside volume developed.
Recent small negative changes in fundamentals have affected Haemonetics Corp (NYSE: HAE): significant quarterly earnings deceleration occurred.
In light of these highly negative signals we are reviewing our current Overall Rating of C. We would view the shares with caution pending completion of this review in the next several days.
Current PriceTarget Research Rating
HAE is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Haemonetics has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Haemonetics has a poor Appreciation Score of 16 but a good Power Rating of 81, resulting in the Low Neutral Value Trend Rating.
Recent Price Action
Haemonetics Corp (NYSE: HAE) stock suffered a very large decline of -6.7% on 11/17/23. The shares closed at $83.21. The stock has been exceptionally strong relative to the market over the last nine months but has declined -2.8% during the last week.
Be the first to comment